5 Steps
Maximum: 2 CME cr.
Sign in to view your progression
Program overview Progr...
Learning objectives Learn...
Credit designation Credi...
Disclosure / Disclaimer Discl...

This E-module on Immunotherapy in gynae-oncology gives the first details of the basic science underlying immunotherapy in gynae cancers (ovarian, endometrial, and cervical cancers) and advise how to manipulate the microenvironment of these malignant tumours. In addition, the mechanism of action of immune checkpoint inhibitors, new targets, and immunotherapeutic method are included. 
An update on immune checkpoint inhibitor therapy as a single agent in ovarian, endometrial, and cervical cancer is presented. Guidelines for the use of immune checkpoint inhibitors are discussed, including those developed by ASCO.
The e-module presents the rationale and clinical trials exploring different immune checkpoint inhibitor combinations with chemotherapy, anti-angiogenics, PARP inhibitors, radiotherapy, and other immunotherapy agents in the different localisation and settings.

The advanced course in Ovarian Cancer Surgery aims to improve the training of surgeons and elevate the standards of knowledge on management of surgical aspects of gynaecological cancers treatment. The advanced theoretical lectures are complemented by explanatory step-by-step videos of surgical techniques by leading experts in the field.

The e-module contains the 4 following lectures. At the end there is a post-test to help you test and improve your knowledge. The number of test attempts is unlimited. 

- Lecture 1: Immunotherapy in gynae-oncology: Why and how?
- Lecture 2: The development of checkpoint inhibitor combinations: Which future?
- Lecture 3: Checkpoint inhibitors in gynaecological cancers: What are the data?
- Lecture 4: How to detect and manage immunotherapy toxicity

You can watch the lectures in any order that you like but you will only have access to the module post-test after viewing all the lectures within the module.

After you have successfully completed the post-test, and the evaluation, you will be able to submit your feedback to the course and print out your CME certificate. 

Obtain knowledge on basic science on immunotherapy, mechanism of action of immune checkpoint inhibitors, new targets, and immunotherapeutic methods.

Acquire comprehensive update of immune checkpoint inhibitor therapy as a single agent and in combinations with other treatments.

Learn on specific indication of immunotherapy in gynae cancers.

Understand how to manage the side effects of the checkpoints inhibitors.

The ESGO Immunotherapy on gynae-oncology e-module, organized by European Society of Gynaecological Oncology (ESGO), is accredited by the EACCME®, the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.

Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited.

Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits(TM).

Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

All speakers have reported no potential conflict of interests. 

Immunotherapy in gynae-oncology: Why and how?
The development of checkpoint inhibitor combinations: Which future?
Checkpoint inhibitors in gynaecological cancers: What are the data?
How to detect and manage immunotherapy toxicity
Final assessment & Evaluation

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies